JTCD attenuates HF by inhibiting activation of HSCs through PPARα-TFEB axis-mediated lipophagy.

• Tác giả: Ying Ding, Yi He, Jiaxin Huang, Wenfang Lan, Xiaofan Liang, Chang Shao, Linmao Ye, Junjie Zhang
• Ngôn ngữ: eng
• Thông tin xuất bản: Germany : Phytomedicine : international journal of phytotherapy and phytopharmacology , 2025
• Bộ sưu tập: NCBI
• ID: 691547

Tóm tắt

BACKGROUND: Hepatic fibrosis (HF) is an intermediate stage in the progression of chronic liver disease to cirrhosis and has been shown to be a reversible pathological process. Known evidence suggests that activation of hepatic stellate cells (HSCs) and degradation of their lipid droplets (LDs) play an indispensable role in the process of HF. Jiawei Taohe Chengqi Decoction (JTCD) can inhibit the activation of HSCs in the process of HF, but the exact mechanism remains to be elucidated. PURPOSE: The aim of this study is to determine whether JTCD inhibits lipophagy and to explore the possible mechanisms of its HF effect in HSCs by regulating the PPARα/TFEB axis. METHODS: Network pharmacology and molecular docking were firstly applied to predict the potential mechanism of JTCD for the treatment of HF. In vivo, a mouse model of HF was constructed using carbon tetrachloride (CCl RESULTS: JTCD effectively alleviated CCl